CART with bispecific T-cell engager (CART.BiTE) cells were engineered to co-express an EGFRvIII-specific CAR and secrete EGFR-targeting BiTEs, enhancing the elimination of heterogeneous glioblastoma tumors. This evidence concerns the gene EGFR and glioblastoma.